Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations

Brooke E. Sanders, Rebecca Wolsky, Elizabeth S. Doughty, Kristen L. Wells, Debashis Ghosh, Lisa Ku, Joseph G. Pressey, Benjamin B. Bitler, Lindsay W. Brubaker

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) is a rare and aggressive disease. While classically linked to mutations in SMARCA4, we describe a case in a patient with both SMARCA4 and BRCA2 germline mutations. We describe her disease presentation, histopathology and treatment with adjuvant systemic chemotherapy, interval hyperthermic intraperitoneal chemotherapy, high dose chemotherapy with stem cell rescue, and maintenance with a poly-ADP-ribose polymerase inhibitor (PARPi). Additionally, we share spatial transcriptomics completed on original tumor.

Original languageEnglish
Article number101077
JournalGynecologic Oncology Reports
Volume44
DOIs
StatePublished - Dec 2022

Keywords

  • PARP inhibitor
  • Small cell carcinoma of the ovary
  • Transcriptomics

Fingerprint

Dive into the research topics of 'Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations'. Together they form a unique fingerprint.

Cite this